Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts
Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/
The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asgar MD, Dr Samir Kapadia MD, and Dr Nicolas van Mieghem MD.
The SAB is chaired by Dr Martin Leon, Professor of Medicine at New York’s Columbia University Irving Medical Center and Chief Innovation Officer and the Director of the Cardiovascular Data Science Center for the Division of Cardiology. Dr. Leon has played a pivotal role in shaping the field of interventional cardiovascular medicine through his involvement in over 50 clinical trials. He has co-authored over 1550 publications and has directed or co-directed over 100 international educational programs focused on interventional cardiology. Dr. Leon's significant contributions to the medical community have been recognized with 10 international career achievement awards, and he has been awarded an honorary degree from the University of Athens.
“I have been impressed by the Protembis management and their innovative US pivotal clinical trial design that utilizes MRI endpoints. I am looking forward to collaborating with the other members of the SAB to advise on the technology’s future evolution as the field of TAVR expands into lower risk, asymptomatic, and younger patients,” said SAB Chair Dr Martin Leon.
Having recently moved from the Montreal Institute of Cardiology where she was medical director of the structural heart program, Dr Anita Asgar is an associate professor and the medical director for structural and interventional cardiology at Northwestern Medicine in Evanston/Chicago, USA. She has published and co-authored almost 200 scientific papers in peer-reviewed journals. Her research interests include the treatment and management of valvular heart disease and cost-effectiveness analyses.
Dr Samir Kapadia is chairman of cardiology in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine in Cleveland. He is the author of more than 80 book chapters in medical textbooks on his specialty interests, and he has authored more than 800 articles in peer reviewed medical journals on his clinical experience. He is editor in chief for the Textbook of Interventional Cardiology. Dr Kapadia has been instrumental in the design and execution of the seminal CEP trials as the Co-Principal Investigator of the Sentinel IDE trial (Boston Scientific, Marlborough, MA, USA) and Principal Investigator of the PROTECTED TAVR Trial. Dr Kapadia is a fellow of the American College of Cardiology, European Society of Cardiology, Society of Vascular Medicine, and a member of the American Heart Association and Society of Thoracic Surgery.
Dr Nicolas Van Mieghem is a professor of medicine and the director of interventional cardiology at the Thoraxcenter Erasmus University Medical Center in Rotterdam. He has published and co-authored over 500 scientific papers in peer-reviewed journals. He was the Principal Investigator of the MISTRAL-C European Trial of the Sentinel™ device and has been author or co-author on almost 30 publications specifically in the field of CEP. He is a principal investigator and steering committee member in multiple ongoing international trials evaluating various coronary and transcatheter valve technologies. Dr Van Mieghem is a fellow of the European Society of Cardiology and the American College of Cardiology.
“We are pleased to announce the creation of this SAB with such a roster of global recognized thought leaders,” said Protembis Co-Chief Executive Officers Karl von Mangoldt and Conrad Rasmus. “To be able to cooperate closely with the members and to benefit from their extensive clinical and strategic knowledge is a privilege. Their guidance will be critical as we map our strategic path forward.”
Protembis is currently enrolling patients in the PROTEMBO Pivotal IDE Trial (NCT05873816), which aims to show that the ProtEmbo® System is superior to contemporary practice in reducing new cerebral lesion volume when assessed by Diffusion-Weighted MRI. The novel trial randomizes ProtEmbo against a hybrid control group: half receiving no CEP and half receiving the Sentinel™ device. The trial is led by Dr Roxana Mehran (Mount Sinai, NY, USA) as the Chair of the Study Executive Committee, with Dr Susheel Kodali (New York Presbyterian Hospital, NY, USA), Dr Raj Makkar (Cedars Sinai, Los Angeles, CA, USA) and Dr Stephan Haussig (Herzzentrum, Dresden, Germany), as the Global Co-Principal Investigators.
About Protembis
Protembis is a privately-held emerging medical device company that has developed the ProtEmbo® Cerebral Protection System. The company strives to provide a simple and reliable solution to protect patients from brain injury during left-sided heart procedures, improving patient quality of life and reducing overall healthcare costs associated with brain injury. The ProtEmbo® System is currently undergoing clinical investigations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317149296/en/
Contacts
Protembis GmbH
Conrad Rasmus & Karl von Mangoldt
Co-CEOs
+49(0)241 9903 3622
management[at]protembis.com
www.protembis.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.protembis.c
om&esheet=54224569&newsitemid=20250317149296&lan=en-US&anchor=www.protembis.com&
index=1&md5=2f0ec091e7835596da2572d3789cf52b
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Storage Now Validated for NVIDIA DGX SuperPOD, NVIDIA Cloud Partners, and NVIDIA-Certified Systems18.3.2025 22:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NVIDIA has validated high-performance NetApp enterprise storage systems with NetApp ONTAP® for environments powering AI training and inferencing. For the first time, with NetApp, customers can now get the benefits of validated configurations and architectures for NVIDIA—including NVIDIA DGX SuperPOD, NVIDIA Cloud Partners, and NVIDIA-Certified Storage—combined with the rich and mature data management services in NetApp ONTAP critical for building AI factories. These certifications ready NetApp to tap the NVIDIA AI Data Platform reference design for NetApp ONTAP to advance storage infrastructure with AI agents for reasoning model inference workloads, powered by NVIDIA accelerated computing, networking, and software. “NetApp and NVIDIA are longstanding technology partners, jointly serving hundreds of customers for AI model training and inferencing,” said Jonsi Stefansson, Senior Vice President and C
NetApp Fuels Future of Agentic AI Reasoning Solutions with NVIDIA AI Data Platform18.3.2025 22:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it is advancing the state of the art in agentic AI with intelligent data infrastructure that taps the NVIDIA AI Data Platform reference design. By collaborating with NVIDIA, NetApp is enabling businesses to better leverage their data to fuel AI reasoning inference. In the era of intelligence, businesses need to rethink their data strategies to turn rapidly growing data estates into competitive assets that empower them to agilely navigate their business environment. By adopting an Intelligent Data Infrastructure framework, businesses will be able to operate under a unified vision that integrates metadata cataloging, automation, and hybrid cloud capabilities to eliminate siloes and deliver actionable insights at every stage of the AI pipeline. Together, NetApp ONTAP® and the NVIDIA AI Data Platform enable businesses to navigate the era of intelligence by building distributed systems that unlock the full
Outseer Launches Platformized Behavioral Biometrics Delivering Unmatched Defense in Depth18.3.2025 21:52:00 EET | Press release
Outseer, a recognized leader in authentication and fraud prevention for digital banking and 3-D Secure (3DS) transactions, announced its platform-native Behavioral Biometrics capability today. The addition of platformized Behavioral Biometrics introduces another layer of defense that continuously analyzes user interactions to detect anomalies in real time. Building on its rich RSA® heritage (formerly RSA Fraud & Risk Intelligence™), Outseer has enhanced its platform to meet today’s dynamic threat landscape. As fraud evolves—spurred by the digitization of payments, the spread of personal data across the dark web, the growing threat of scams and authorized fraud, as well as advancements like GenAI—Outseer’s multi-signal risk engine, leveraging sophisticated machine learning algorithms and AI, sets a new standard for continuous, unified protection. “Our customers are facing rising authorized and unauthorized fraud threats in digital banking and 3DS transactions, requiring fraud solutions
Ravenna Becomes the First Colourblind-Friendly City in Italy: Event and New EnChroma Glasses Donation18.3.2025 18:29:00 EET | Press release
Tomorrow, March 19, 2025, at 4:30 PM, the conference "How Colourblind People See" will be held at the Martini Hall of MAR – Ravenna’s Museum of Art. This event is dedicated to raising awareness about colour blindness and the challenges of colour perception. Speakers will include Stefano De Pietro, President of the Italian Association "How Colourblind People See", and Sandor Breznay, President of the Breznay-Ganoczy Foundation (Agno, Switzerland) and the Paolina Brugnatelli Foundation (Milan). Colour blindness affects approximately 1 in 12 men and 1 in 200 women, with over 300 million people worldwide experiencing this condition—2.5 million in Italy. While those with normal colour vision can distinguish over a million shades, individuals with colour vision deficiency see only about 10% of those hues. As a result, colours may appear dull or even indistinguishable. This initiative aims to increase public awareness and make cultural and educational experiences more accessible for those wit
Accelera hosts Spanish Prime Minister and industry leaders for tour and meeting at Guadalajara electrolyzer facility18.3.2025 18:10:00 EET | Press release
Accelera™ by Cummins, the zero-emissions business segment of Cummins Inc. [NYSE: CMI], hosted Spanish Prime Minister Pedro Sánchez and other government officials at its state-of-the-art electrolyzer manufacturing facility in Guadalajara, Castilla-la Mancha, Spain. The visit highlighted Accelera's important role in enabling the European Union (EU) and Spain's energy transition toward a sustainable future. Following Prime Minister Sánchez’s visit, Accelera held a meeting with top industry executives to explore opportunities for advancing the Spanish green hydrogen market together. The Government of Spain is committed to the green transition, with green hydrogen as one of its pillars. The decisive policies promoted by the Executive have allowed 20% of green hydrogen projects in Europe to be promoted in Spain. Prime Minister Sánchez toured the 260,000 square-foot proton exchange membrane (PEM) electrolyzer manufacturing facility, one of the largest in Spain, and met with Accelera employees
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom